ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center

ECOG-ACRIN 胸部恶性肿瘤综合转化科学中心

• 批准号: 9894764
• 负责人: DAVID P. CARBONE
• 金额: $ 75.08万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-03-14 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9894764
• 关键词: American College of Radiology Imaging Network; Area; Award; BRAF gene; Biological Markers; Center for Translational Science Activities; Chest; Clinical; Clinical Data; Clinical Sciences; Clinical Trials; Clinical Trials Network; Collaborations; Combined Modality Therapy; Detection; Development; Disease; EGFR inhibition; Early Diagnosis; Eastern Cooperative Oncology Group; Enrollment; Epidermal Growth Factor Receptor; Excision; Funding; Genomics; Goals; Grant; Immunologic Markers; Immunotherapy; Institution; Leadership; Lung; Lung Neoplasms; Malignant neoplasm of lung; Malignant neoplasm of thorax; Molecular; Molecular Abnormality; Molecular Analysis; Mutation; National Clinical Trials Network; Non-Small-Cell Lung Carcinoma; Operative Surgical Procedures; Patient-Focused Outcomes; Patients; Pilot Projects; Plasma; Plasma Cells; Play; Precision Medicine Initiative; Precision therapeutics; Prevention; Process; Proteomics; ROS1 gene; Recurrence; Research; Research Personnel; Residual Neoplasm; Resistance; Risk; Risk stratification; Role; STK11 gene; Science; Specimen; Technology; Testing; Time; Translational Research; Work; biomarker development; biomarker discovery; biomarker evaluation; biomarker-driven; cell free DNA; checkpoint inhibition; chemotherapy; clinical care; cohort; companion diagnostics; driver mutation; drug development; epigenetic marker; epigenomics; improved; improved outcome; inhibitor/antagonist; innovation; lung cancer screening; lung small cell carcinoma; next generation; novel; novel marker; novel strategies; personalized medicine; phase 3 study; programmed cell death ligand 1; programs; prospective; targeted agent; targeted treatment; tumor

PROJECT SUMMARY/ABSTRACT The ECOG-ACRIN Thoracic Integrated Translational Research Center (EA-ITSC) comprises a team of accomplished researchers with a proven track record of collaborative work to improve outcomes for patients with lung cancer. The EA-ITSC, funded in 2014 by the NCI (U10) at the same time as the formation of the National Clinical Trials Network (NCTN), has played a major role in developing novel approaches for risk stratification, molecular testing, and treatment of lung cancer. This group has also been responsible for guiding the development of biomarker-driven clinical trials initiated by the ECOG-ACRIN Thoracic Malignancies Committee. Our highly collaborative team approach includes sharing specimens across institutions, conducting pilot projects that are of direct relevance to NCTN trials and guiding the translational research components of all newly developed ECOG-ACRIN thoracic malignancies trials. Our overarching goal is to develop novel biomarkers to enhance the efficacy of immunotherapy, overcome resistance to targeted agents and to identify combination treatment approaches to enhance the efficacy of existing therapies in lung cancer within the context of the NCTN. With this application, we propose to continue our research work with direct relevance to the NCTN, with the following specific aims: 1) To develop genomic, epigenomic, and proteomics approaches to enhance biomarker discovery efforts in ongoing and planned ECOG-ACRIN studies; 2) To conduct pilot studies on existing ECOG- ACRIN and institutional lung cancer tumor specimens that will lead to prospective NCTN clinical trials; and 3) To guide the development of translational research components of ECOG-ACRIN Thoracic trials and promote collaborations with lung cancer SPORE and P01 institutions. The EA-ITSC will have a robust pilot projects program from years 2-6 of this award that will invite participation from all the NCTN network groups, institutions with lung cancer SPORE and P01 awards, to bring the best science to NCTN clinical trials.

项目摘要/摘要 Ecog-acrin胸部综合翻译研究中心（EA-ITSC）组成了一个团队 有经验的研究人员具有协作工作的良好记录，以改善患者的结局 肺癌。 EA-ITSC，由NCI（U10）于2014年与国家组成的同时资助 临床试验网络（NCTN）在开发新型风险分层方法中发挥了重要作用， 分子测试和肺癌的治疗。该小组还负责指导 由ECOG-ACRIN胸部恶性肿瘤委员会发起的生物标志物驱动的临床试验的开发。 我们高度协作的团队方法包括在机构之间共享标本，进行试点项目 与NCTN试验并指导所有新的转化研究组件的直接相关性 开发了Ecog-Acroin胸部恶性肿瘤试验。我们的总体目标是开发新颖的生物标志物 增强免疫疗法的疗效，克服对靶向剂的耐药性并确定组合 在NCTN的背景下，治疗方法增强了现有疗法在肺癌中的功效。 通过此应用，我们建议继续与NCTN直接相关的研究工作，与 以下特定目的：1）开发基因组，表观基因组学和蛋白质组学方法来增强生物标志物 在正在进行和计划的ECOG-ACRIN研究中发现的工作； 2）对现有的ECOG进行试点研究 - ACRIN和机构肺癌肿瘤标本将导致前瞻性NCTN临床试验；和3）到 指导Ecog-acrin胸试验的转化研究组成部分的发展并促进 与肺癌孢子和P01机构的合作。 EA-ITSC将有一个强大的飞行员项目 该奖项2 - 6年的计划将邀请所有NCTN网络组，机构的参与 通过肺癌孢子和P01奖，将最好的科学带入NCTN临床试验。